Randomised Controlled TrialtaVNSn = 76

Transcutaneous Vagus Nerve Stimulation (tVNS) for Treatment of Drug-Resistant Epilepsy: A Randomized, Double-Blind Clinical Trial (cMPsE02)

Bauer S, Baier H, Baumgartner C, Bohlmann K, Fauser S, Graf W, Hillenbrand B, Hirsch M, Last C, Lerche H, et al.

Brain stimulation · 2016

Key finding

Patients completing 20 weeks of 25 Hz taVNS achieved a 34.2% seizure reduction, though the primary superiority endpoint over 1 Hz control was not met.

Condition
Epilepsy
Stimulation
taVNS
Evidence tier
Randomised Controlled Trial
Participants
76
View on PubMed

Cite this study

Bauer, S., Baier, H., Baumgartner, C., Bohlmann, K., Fauser, S., Graf, W., Hillenbrand, B., Hirsch, M., Last, C., Lerche, H., Mayer, T., Schulze-Bonhage, A., Steinhoff, B., Weber, Y., Hartlep, A., Rosenow, F., & Hamer, H. (2016). Transcutaneous Vagus Nerve Stimulation (tVNS) for Treatment of Drug-Resistant Epilepsy: A Randomized, Double-Blind Clinical Trial (cMPsE02). Brain stimulation.

Related studies in Epilepsy

Summary by Vagus Research. Always consult the primary source for the authoritative record.

Stay Current with the Research

Join researchers and practitioners exploring the science of vagus nerve stimulation. Receive curated research summaries and evidence updates.

No spam. Unsubscribe at any time. We respect your privacy.